
Daniel Gerlach
@gerlach_d
Associate Scientific Director, Computational Biology Oncology at @boehringer ๐งฌ Data Scientist & KRAS, MDM2 , HER2 Research. Tweets are my own.
ID: 1325200380
https://www.linkedin.com/in/daniel-gerlach 03-04-2013 18:40:12
8,8K Tweet
1,1K Followers
505 Following


Always great to hear the original RAScal Channing Der Der Lab at UNC talk about KRAS & KRAS inhibitors. Thanks to Channing and his team for putting together such great overview slides. As of March 2025, there are 45 inhibitors (!) & 160 clinical trials. Absolutely amazing. David S. Hong MD


Wow, 160 clinical trials involving agents targeting RAS/KRAS! Norbert Kraut

EGFR mutation is no more a straightforward story. 3 options in 1L, many options in 2L. perez oliveros #ELCC25


#ELCC25 Ph I Daraxonrasib (RAS-On panRAS inhibitor) in RAS+ NSCLC: - ORR 38% - mPFS 9.8m, mDOR 15.1m - modest tox (diarrhea & rash) - 200mg dose selected for ph III Promising. Delighted Ph III RASolve trial of this agent, coming to ๐ฎ๐ช ESMO - Eur. Oncology CancerTrialsIreland ๐ @Oncoalert #LCSM





T-DXd approval finally expanded also in Europe to patients with HR+/HER2-0 (ultralow) disease or chemo-naive pts. Appealing post-ET option for patients with aggressive disease course. Congrats G Curigliano MD PhD for leading the DB06 trial that backed this approval! astrazeneca.com/media-centre/pโฆ


๐งฌ๐ก The EMBL Conference 'Cancer genomics' is now open for registration! Submit your abstract by 13 July and join the community of leading scientists and academic clinicians working on cancer genomics ๐ฉ๐พโ๐ฌ๐จ๐ปโ๐ฌ #EMBLCanGen ๐๏ธ 11 โ 14 November 2025 ๐ EMBL Heidelberg and Virtual


โญ๏ธWith so many KRAS targeted drugs entering clinical trials pleased to share our editorial ๐๐ผReady, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer ๐๐งฌ๐ฏ | JCO Oncology Practice JCO Oncology Practice ASCO OncoDaily ascopubs.org/doi/full/10.12โฆ








I know #AACR25 is coming up, but the program and roster for AACR Special Conference on #PancreaticCancer in Boston in the fall of 2025 is also up and available.... the attendance at this just keeps growing! Dr. Edna Cukierman, Ph.D. Laura DeLong Wood aacr.org/meeting/aacr-sโฆ